Initiated analytical studies in Q4 2024to prepare for a potential Biosimilar Biological Product Development (“BPD”) Type 2a meeting with the ...

The global axial spondyloarthritis market is set for significant growth, with forecasts indicating a robust CAGR of 14.8% during the period from 2022 to 2028. This growth is primarily attributed to ...

Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and ...

This article is authored by Dr YK Gupta, president, AIIMS, Jammu and Ankush Kapoor, founder & CEO, Pharma NXT Biotech.

J&J JNJ announced plans to invest more than $55 billion over the next four years to expand its manufacturing footprint in the ...